• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    DHMH recognizes World Hepatitis Day
    Hepatitis C (HCV) medications now available for specific clients

    BALTIMORE, MD (July 28, 2016) – The Department of Health and Mental Hygiene (DHMH), the Prevention and Health Promotion Administration (PHPA), and the Infectious Disease Prevention and Health Services Bureau (IDPHSB) join the nation in the observance of World Hepatitis Day on July 28, 2016.  At this time, DHMH is proud to formally announce the expansion of the Maryland AIDS Drug Assistance Program (MADAP) formulary to include medications for hepatitis C. This action allows MADAP clients access to treatments known to cure hepatitis C in as little as 12-24 weeks. Hepatitis C medications added to the formulary in April 2016 include: 

    • Harvoni (ledipasvir/sofosbuvir)
    • Viekira Pak
    • Sovaldi (sofosbuvir)
    • Ribavirin
    • Zepatier


    “We are pleased to be able to include medications to the list of treatments available to Maryland residents co-infected with HIV and HCV who are enrolled in our MADAP program,” said Deputy Secretary for Public Health Services, Dr. Howard Haft.
    According to the Centers for Disease Control and Prevention, about 25% of people living with HIV are co-infected with HCV.[1] HIV/HCV co-infection increases the risk for liver disease, liver failure, and liver-related death.
    “The Infectious Disease Prevention and Health Services Bureau is committed to working with health professionals and community stakeholders to ensure that Marylanders co-infected with HIV and HCV have access to medications that allow them to prevent life-threatening complications,” said Bureau Director, Jeffrey Hitt. Marylanders with HIV are encouraged to call 410-767-6535 or 1-800-205-6308 to learn more about the MADAP Program.
    Additionally, for World Hepatitis Day this year, DHMH urges baby boomers—persons born from 1945 through 1965—to get an HCV test. Although anyone can contract HCV, 75% of adults infected with the virus are baby boomers. Learn more about baby boomers and HCV by clicking here. DHMH’s Maryland Community-Based Programs to Test and Cure Hepatitis C, a CDC-sponsored initiative, is a collaboration
    between public health, primary care, and specialty care to provide access to quality HCV screening and treatment.
    For the Maryland AIDS Drug Assistance Program (MADAP) Formulary visit: http://goo.gl/53ZObZ; and for Hepatitis resources go to: http://www.cdc.gov/hepatitis/index.htm.